Maxim Group Issues Positive Forecast for Sensus Healthcare (NASDAQ:SRTS) Stock Price

Sensus Healthcare (NASDAQ:SRTS) had its target price upped by Maxim Group from $12.00 to $14.00 in a research report sent to investors on Friday, Marketbeat reports. They currently have a buy rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Sensus Healthcare in a research note on Monday, August 12th.

Sensus Healthcare Stock Performance

Shares of Sensus Healthcare stock traded up $0.35 on Friday, reaching $7.64. 796,533 shares of the company were exchanged, compared to its average volume of 275,852. Sensus Healthcare has a 1-year low of $2.02 and a 1-year high of $8.29. The company’s 50-day moving average is $6.37 and its two-hundred day moving average is $5.94. The firm has a market cap of $125.22 million, a price-to-earnings ratio of 18.63 and a beta of 1.04.

Institutional Trading of Sensus Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC increased its position in shares of Sensus Healthcare by 8.5% in the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock worth $849,000 after acquiring an additional 11,525 shares in the last quarter. XTX Topco Ltd increased its stake in shares of Sensus Healthcare by 76.0% during the 3rd quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock worth $183,000 after purchasing an additional 13,619 shares during the last quarter. Truvestments Capital LLC bought a new position in Sensus Healthcare during the third quarter valued at about $32,000. Cubist Systematic Strategies LLC acquired a new stake in Sensus Healthcare in the 2nd quarter worth approximately $156,000. Finally, Marshall Wace LLP lifted its stake in shares of Sensus Healthcare by 152.4% in the second quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock worth $412,000 after buying an additional 46,732 shares during the last quarter. Institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.